Loraped

Quick links to important sections

Loraped

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loraped

Property Description
Active Ingredients Loratadine, Phenylephrine Hydrochloride
Form Oral preparation (Syrup, Tablets, Capsules)
Pharmacological Class H1 Antihistamine and Sympathomimetic Amine
Common Use Temporary relief of upper respiratory and allergic symptoms
Origin Synthetic

1. What Type of Medicine is Loraped?

Loraped is a synthetic fixed-dose combination product intended for systemic administration that belongs to the pharmacological class of H1 Antihistamine and Sympathomimetic Amine (decongestant) combinations. This medicine integrates two distinct active ingredientsLoratadine and Phenylephrine Hydrochloride—within a single preparation. The combination of ingredients is clinically recognized for addressing both allergic and congestive symptoms, with Loratadine being officially classified as a second-generation antihistamine. The drug is available as an oral preparation, notably including a syrup form in addition to standard tablets and capsules.

2. The Dual Composition and General Purpose of Loraped

The composition is formulated to address combined upper respiratory symptoms, such as those associated with seasonal allergic rhinitis. The Loratadine component is responsible for competitive inhibition, which is the fundamental mechanism for preventing the chemical cascade that causes sneezing and itching. The inclusion of Phenylephrine Hydrochloride provides the intended sympathomimetic activity, historically used to reduce swelling by inducing vasoconstriction (narrowing of blood vessels) in the nasal mucosa. However, it is an important factual note that the efficacy of orally administered phenylephrine as a decongestant at standard doses has been a subject of recent re-evaluation. This combination is thus chiefly relied upon for its Loratadine content to alleviate the immunological symptoms of allergy.

Regulatory References

  1. [PubChem]
  2. [NIH]
  3. [FDA]
  4. second-generation antihistamine

What side effects are possible with Loraped?

Possible Side Effects and Safety Information

The safety profile of this fixed-dose combination reflects the known adverse reactions of its two components, Loratadine and Phenylephrine Hydrochloride, as classified in official regulatory documents. Adverse reactions are grouped by the physiological system affected and their expected frequency.

Officially Documented Adverse Reactions

The most common adverse reactions documented in regulatory safety data often involve the Nervous System and General Disorders, including headache, somnolence (drowsiness), fatigue, and dry mouth. These effects are generally classified as Common.

Less frequently reported reactions, often classified as Uncommon, are primarily related to the stimulating effects of the sympathomimetic component. These effects include insomnia, tachycardia (increased heart rate), palpitations, and nervousness.

Serious Safety Considerations

The regulatory record includes documentation of rare but serious adverse reactions. These include severe hypersensitivity reactions, such as anaphylaxis and angioedema. Furthermore, severe mucocutaneous reactions and cases of hepatic function abnormal have been documented in association with the active ingredients.

Population-Specific Safety and Restrictions

Official labeling contains specific notes for certain patient populations. Older adults may have an increased susceptibility to the cardiovascular and central nervous system effects of the sympathomimetic component. For patients with renal or hepatic impairment, the clearance of Loratadine may be reduced.

This medicine is strictly contraindicated in individuals with severe pre-existing conditions, including severe hypertension and severe coronary artery disease. It is also contraindicated for use in patients concurrently taking Monoamine Oxidase (MAO) inhibitors, due to the substantial risk of a hypertensive crisis.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose of Loraped, a combination of Loratadine and Phenylephrine, necessitates immediate medical attention. Individuals must get medical help or contact a Poison Control Center right away, as stated in the prescribing information.

Overdose Scope

Feature Official Regulatory Statement
Documented overdose presentations Symptoms include somnolence, tachycardia, headache, and anticholinergic symptoms from Loratadine, alongside hypertension, anxiety, and nausea from Phenylephrine.
Physiological systems affected Effects involve the Cardiovascular system (e.g., cardiac arrhythmia, hypertensive crisis) and the Central Nervous System.
Dose-related or exposure-related factors Taking more than directed may cause drowsiness; large overdoses are associated with cardiovascular risk.
Population-specific overdose notes Assessment is required for children or young people with intentional self-poisoning or significant accidental ingestion.

Management and Required Actions

  • The official protocol mandates that treatment for overdosage should be started immediately, focusing on general symptomatic and supportive measures.
  • Monitoring requirements may include cardiac monitoring and ECG assessment due to the risk of severe cardiovascular effects.
  • Decontamination steps such as the administration of activated charcoal or gastric lavage may be considered by medical professionals.
  • While no specific antidote is known for Loratadine, specific interventions, such as the use of phentolamine, are described for managing severe hypertension caused by the Phenylephrine component.

The overall overdose profile is defined by the regulatory documents through the listing of these dual-component symptoms and the requirement for immediate help-seeking due to the potential for serious outcomes.

Therapeutic Uses of Loraped

What Loraped Treats: Main Uses and Benefits

Combination products are used for symptomatic management in contexts involving nasal congestion and allergic symptoms. Loraped is applied across therapeutic domains where patients experience symptoms related to inflammatory or irritative states alongside airway obstruction.

Addressing Combined Symptom Burdens

Loraped is commonly used for managing the complex symptoms of seasonal and perennial allergic rhinitis when patients experience both allergic reactions and physical obstruction simultaneously. It is applied across conditions where symptom clusters appear suddenly or fluctuate, including runny nose, frequent sneezing, itchy nose, and a stuffy nose. This combination of use contributes to easing the overall symptom load.

“This approach is relevant when supportive symptom management is appropriate, particularly when the patient faces both irritation and congestion.”

It is relevant for managing challenging symptoms associated with the common cold and upper respiratory allergies.

Quick Fact: Relief for Combined Discomfort
Supports the patient during episodes of heightened discomfort and assists with maintaining functional stability when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

The official eligibility profile for Loraped is defined by specific population contraindications and usage restrictions documented by regulatory bodies. The medicine is contraindicated for patients with known hypersensitivity to its components, or for those with severe, uncontrolled cardiovascular conditions, including severe hypertension, severe coronary artery disease, and thyrotoxicosis. Use is strictly prohibited in patients currently taking or who have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.

Eligibility is generally established for adults and adolescents aged 12 years and older. Use in children younger than 12 years is not established for the fixed-dose combination product. Older adults should have their renal function evaluated, as advised by regulatory monographs.

The label advises caution or non-use for specific physiological states. The medicine is not recommended for patients with severe hepatic impairment or severe renal insufficiency. Caution is required for individuals with diabetes, prostate enlargement, or certain forms of glaucoma. During pregnancy, use is conditional, recommended only if clearly needed. For nursing mothers, a decision must be made to either discontinue breastfeeding or discontinue the drug, as both components are excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Loraped is defined by the distinct actions and metabolism of its two active ingredients: Loratadine and Phenylephrine Hydrochloride.

Drug-Drug Interaction Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the severe risk of potentiating the pressor effects of Phenylephrine Hydrochloride. Treatment with Loraped must not commence until at least 14 days after discontinuing an MAOI.

Pharmacokinetic Exposure Alteration

Concurrent use with inhibitors of cytochrome P450 enzymes, specifically CYP3A4 and CYP2D6 (e.g., Ketoconazole, Erythromycin, Cimetidine), results in reduced clearance of Loratadine. This pharmacokinetic interaction outcome is a substantially increased plasma concentration of Loratadine.

Pharmacodynamic Potentiation

Interactions primarily related to the Phenylephrine component involve the potentiation of cardiovascular effects. Other Sympathomimetic Agents, Tricyclic Antidepressants, and Ergot Alkaloids may increase the vasopressor response, leading to a risk of adverse cardiovascular outcomes.

Non-Medicinal and Procedural Constraints

Food intake is officially documented to alter Loratadine's exposure, increasing the Area Under the Curve ( AUC) by approximately 48% and delaying the time to maximum concentration ( Tmax). Furthermore, the combination product is not recommended for patients with severe liver impairment due to the differential effect on the clearance of the two components. Loratadine may also suppress the result of allergy skin tests and requires a 48-hour discontinuation period before testing.

Mechanism of Action

The dual mechanism of Loraped relies on the complementary actions of its two components: H1 inverse agonism and alpha1 adrenergic agonism. Loratadine functions as a selective inverse agonist at peripheral Histamine H1-receptors. By stabilizing these receptors in an inactive state, the molecule limits the activity of the endogenous mediator Histamine, thereby inhibiting the signal transduction associated with increased capillary permeability and peripheral nociceptive activation. The drug's structural properties restrict its crossing of the blood-brain barrier, ensuring peripheral focus. The second component, Phenylephrine, acts as a direct agonist on Alpha-1 (alpha1) Adrenergic Receptors located on vascular smooth muscle cells in the nasal mucosa. Activation of these receptors induces vasoconstriction, causing a reduction in local blood volume and pressure within the engorged tissue. This targeted vascular modulation results in the physical shrinkage of mucosal tissue. The synergy of the two mechanisms influences both the upstream chemical mediator pathway and the downstream physiological vascular pathway simultaneously.

Dosage and Administration Information

How Loraped is Used: Official Administration Guidelines

Loraped, a combination product containing Loratadine and Phenylephrine Hydrochloride, is administered orally and is available in forms such as syrup and tablets. The proper use of this medicine is structured by established protocols related to dosing schedules, population-specific adjustments, and administration conditions.

The standard regimen for adults and children aged 12 years and older is based on the 10 mg dose of the Loratadine component and is typically scheduled for Once Daily (qDay) administration. This frequency aligns with the established duration of action for the antihistamine component. Pediatric dosing for children aged 2 to 12 years is determined by body weight, where those weighing 30 kg or less receive a lower 5 mg dose of the Loratadine component.


Official Administration and Contextual Rules

Administration Rule Procedural Detail
Dosing Frequency Administered Once Daily, regardless of the specific combination form.
Timing Relative to Meals May be taken without regard to mealtime.
Severe Organ Impairment The dosing interval must be extended for patients with severe hepatic or renal dysfunction.

Liquid formulations require the use of a dedicated measuring device to ensure accurate dose volume is administered. Furthermore, guidelines advise discontinuing the medicine at least 48 hours before scheduled skin allergy testing, as the antihistamine component can interfere with test results. The overall protocol emphasizes that the medicine is for short-term use, and the recommended dose or frequency must not be exceeded.

The procedural structure dictates determining the appropriate weight- or organ-status-based dose, accurately measuring the required volume or unit, and swallowing the medicine orally at the defined once-daily interval.

Recent Clinical Evidence

Research evidence / Overview of Studies for Loraped


Evidence for Managing Allergic Symptoms (Non-Congestive)

Research exploring how symptoms change over time for the non-congestive symptoms of allergic rhinitis (such as sneezing, itching, and watering eyes) primarily focuses on the Loratadine component of the medicine. Studies have used Randomized Controlled Trials (RCTs) and systematic reviews, which are relevant in trials assessing short-term or episodic symptom patterns related to seasonal and perennial allergies. Regulators have characterized the evidence consistency for the monotherapy component as High. Research provides insight into short-term changes and helps contextualize how patients reported their experience.

Evidence for Treating Nasal Congestion / Stuffy Nose

Research examined the decongestant component, phenylephrine, for its use in conditions involving periods of heightened symptoms, such as nasal congestion. Findings indicate that the overall body of evidence related to the orally administered decongestant component at standard doses is characterized by a low level of consistency regarding measured patient-reported symptom change. Multiple studies, including those reviewed by regulatory bodies, described patterns where the component did not demonstrate a significant difference from placebo in scores related to perceived congestion. Key regulatory advisory bodies have documented limitations in the evidence for symptom change for this component.


Study of the Combined Symptom Burden and Research Gaps

The fixed-dose combination product was evaluated in trials designed to address conditions where both allergic irritation and physical obstruction are present, monitoring a Total Symptom Score (TSS). The evidence is generally characterized as Moderate, reflecting the consistency of research related to the antihistamine component alongside the documented limitations related to the decongestant component's measured outcomes.

What is Still Uncertain: The primary research gap concerns whether the inclusion of the oral decongestant component results in a statistically significant difference in measured outcomes when compared to taking the established antihistamine component alone. Furthermore, evidence remains limited regarding patterns of use or symptom changes over extended periods, and long-term effects are not fully established for the fixed-dose combination.

Key Studies & References MedlinePlus Drug Information: Loratadine and Pseudoephedrine Tablet

Frequently Asked Questions (FAQ)

Common questions about Loraped (FAQ)

Q: What exactly is Loraped prescribed for?

According to the official product information, Loraped is indicated for the temporary relief of symptoms associated with hay fever or other upper respiratory allergies. These symptoms include common allergic reactions such as runny nose, sneezing, itchy/watery eyes, and also nasal congestion. The combination of ingredients is intended to influence both the allergic response and the associated sinus swelling.


Q: Is Loraped a type of antibiotic or something else?

Loraped is not an antibiotic. It is officially classified as a combination product that acts as both an Antihistamine (Loratadine) and a Nasal Decongestant (Phenylephrine). The antihistamine component is associated with relief from allergy symptoms, and the decongestant component is associated with relieving nasal blockage.


Q: How quickly does Loraped start to work after I take it?

Official information indicates that the antihistamine component, Loratadine, typically begins to show an effect within 1 to 3 hours after it is taken. Maximum effect is generally reached some hours after initial effect begins. This timeframe is based on clinical studies of the drug's components.


Q: Can Loraped be taken at the same time as cold medicine?

Regulatory documents advise against taking Loraped with other Sympathomimetic Agents. This is a category of medicines often found in decongestant cold and flu products. Combining them may increase the risk of potentiated cardiovascular effects, and official guidance emphasizes the importance of reviewing ingredient labels.


Q: Are there certain foods or drinks I need to avoid while taking Loraped?

Official documents note that food intake can alter the way the loratadine component is processed by the body, potentially leading to increased overall exposure. However, regulatory guidelines do not explicitly direct the avoidance of specific foods or drinks when taking this product.


Q: What are the most common side effects people report with Loraped?

The most frequently reported potential adverse effects associated with the drug's components include headache, dizziness, and minor gastrointestinal distress such as nausea. Drowsiness may also occur, especially if the recommended dosage or frequency is exceeded. This information is based on the official safety profile.


Q: Does Loraped cause drowsiness or make you tired?

While the product is often labeled as non-drowsy when taken correctly, regulatory warnings do indicate that drowsiness is a potential adverse effect. This effect may be more likely to occur if the recommended dose or frequency is exceeded.


Q: Is it normal to feel slightly nauseous when first starting Loraped?

Gastrointestinal distress, which includes feelings of nausea, is listed in regulatory documents as one of the potential adverse effects of the drug's components. Nausea is a symptom included in the established safety profile.


Q: Can Loraped affect my ability to drive?

Because the drug has the potential to cause side effects such as drowsiness or dizziness, official documents advise caution. When performing tasks that require mental alertness, such as driving or operating machinery, awareness of this possibility is suggested.


Q: Is Loraped safe for use in older adults?

Official information indicates that older adults may have approximately 50% greater overall exposure to the drug's components compared to younger adults. Because of this change in processing, older adults may be more susceptible to experiencing certain side effects like somnolence (drowsiness).


Q: Can Loraped cause problems with sleep or insomnia?

Regulatory documents list sleeplessness, often referred to as insomnia, as a potential adverse effect associated with the product's components. This information is noted in the established safety profile.


Q: Is Loraped safe to use if I have liver problems?

Regulatory guidelines advise that individuals with liver or kidney disease should consult a doctor before using Loraped. Official information states that the dosing interval must be extended for patients diagnosed with severe hepatic dysfunction (severe liver problems).


Q: Are there any known issues with taking Loraped if I have kidney problems?

Regulatory guidelines advise that individuals with liver or kidney disease should consult a doctor before using Loraped. Official information states that the dosing interval must be extended for patients diagnosed with severe renal dysfunction (severe kidney problems).


Q: What is the category or classification of Loraped (e.g., pain reliever, allergy, etc.)?

Loraped is officially classified as a combination product containing an Antihistamine (to treat allergy symptoms) and a Nasal Decongestant (to relieve congestion). It is not classified as a pain reliever or an antibiotic.


Q: How is Loraped eliminated from the body?

Studies on the drug components indicate that approximately 80% of the active components and their metabolic products are eliminated from the body within 10 days. This elimination occurs roughly equally through both the urine and feces.


Q: What type of research studies support the use of Loraped?

The safety and effectiveness profile is established through various clinical investigations, including studies described as placebo-controlled, double-blind trials. These trials examine the product's use for symptoms related to allergic rhinitis.


Q: Has Loraped been studied in large populations?

Official documents confirm that clinical studies of the drug's components have involved various populations. This includes placebo-controlled trials with both pediatric subjects and a range of adult subjects for seasonal allergic rhinitis.


Q: Does Loraped contain any ingredients like gluten or lactose?

The official documentation for the tablet formulation of the single component (Loratadine) lists excipients such as lactose and corn starch. The recommendation is to review the full ingredient list for the specific Loraped product form being considered.


Q: Is Loraped available over the counter?

The product is categorized in the U.S. regulatory system as a HUMAN OTC DRUG, meaning it is available for purchase without requiring a prescription. This classification applies to the specific dosage form and strength that has been approved for over-the-counter use.


Q: Can I take Loraped while pregnant or breastfeeding?

Regulatory warnings uniformly state that individuals who are pregnant or breast-feeding must consult a health professional before using this product. This is a standard warning related to the potential effects of the drug's components on the fetus or nursing infant.


Q: Are there any long-term side effects associated with taking Loraped?

Regulatory information indicates the product is intended for the temporary relief of symptoms and advises that users should stop use if symptoms do not improve within 7 days. The drug's safety profile is established for this intended short-term use, and prolonged use is not officially recommended.


Q: Can Loraped affect blood pressure readings?

Official warnings advise consumers with pre-existing high blood pressure to consult a doctor before use. This is because the decongestant component is classified as a sympathomimetic agent, which has the potential to cause adverse cardiovascular effects and influence blood pressure.


Q: What is the meaning of the [specific medical term] sometimes used to describe Loraped?

The loratadine component is often described using the technical term H1-receptor antagonist. In plain language, this means the drug blocks the action of the chemical Histamine at the H1 receptors. Histamine is the naturally occurring substance responsible for triggering many common allergy symptoms.


Q: What age group is Loraped typically studied in?

Official documentation of clinical studies for the product's components includes subjects across a wide age range. This includes pediatric subjects as young as 2 years old, extending up to older adults (geriatric populations).


Q: Is Loraped considered a new drug or has it been around for a while?

The active ingredients are not new discoveries; the antihistamine component, loratadine, has been available for several decades. It received approval for over-the-counter use in the U.S. in 2002.


Q: What should I avoid doing right before or after taking Loraped?

Regulatory documents emphasize two main avoidance criteria: not taking the product for at least 14 days after stopping a Monoamine Oxidase Inhibitor (MAOI), and strictly avoiding taking more than the recommended dose. These are important for safety.


Q: Can Loraped make you feel dizzy?

Yes, dizziness is listed in regulatory documents as a potential adverse effect associated with the drug. This is noted as part of the established safety profile.


Q: What are the signs of an allergic reaction to Loraped?

Regulatory warnings state that if signs of an allergic reaction occur, such as hives, swelling, or difficulty breathing, the product should be stopped immediately. In such cases, official documentation advises seeking immediate medical attention.


Q: Is Loraped listed as a controlled substance?

The product is categorized as an Over-the-Counter (OTC) drug in the U.S. and is not listed in the Drug Enforcement Administration (DEA) schedules. This means it is not classified as a controlled substance.


Q: Does taking Loraped affect lab test results?

Official documents confirm that the antihistamine component can interfere with the results of allergy skin tests. Regulatory guidelines state the product must be discontinued 48 hours prior to such testing. No similar effect is commonly noted for other routine lab tests.


Q: What is the typical timeframe for a full course of Loraped?

The product is officially indicated for the temporary relief of symptoms. Regulatory guidance suggests that if symptoms do not improve within 7 days or are accompanied by a fever, use should be discontinued.


Q: Does Loraped have a Black Box Warning, and what does it mean?

Official documents confirm that a Black Box Warning is not present on the product label. This type of warning is the most serious form of caution issued by the FDA for drugs with serious or life-threatening risks.


Q: Can I use Loraped if I am a diabetic?

Official warnings advise consumers with diabetes to consult a doctor before use. This is because the decongestant component is a sympathomimetic agent, a class of drugs that may cause an increase in blood glucose concentrations.

How should Loraped be stored and disposed of?

How to Store and Dispose of Loraped?

The official regulatory labeling defines specific conditions for the storage and handling of this medication to maintain its stability.

Required Storage and Protection

Loraped must be stored at Controlled Room Temperature, which is mandated to be 20°C to 25°C (68°F to 77°F). The product must be protected from excessive moisture and stored in a dry place. Furthermore, it should be shielded from light and must not be frozen. To ensure product integrity, the medicine must be kept in its original container with the cap tightly closed, and unused or expired product must be disposed of.

Safety and Disposal

All official labels include the mandate to Keep out of reach of children. Unused medicine and waste material must be discarded in accordance with local regulations and must not be flushed or allowed to enter sewer systems or the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loraped found in:

A-Z Index: